CanSino Biologics Inc. (HKG:6185)

CanSino Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,080	2,023	2,822	3,465	5,645	4,447
Short-Term Investments	323.79	-	-	-	275.2	-
Trading Asset Securities	1,387	1,182	1,308	2,482	1,862	666.64
Cash & Short-Term Investments	2,791	3,204	4,130	5,947	7,783	5,114
Cash Growth	-14.99%	-22.41%	-30.55%	-23.59%	52.19%	577.49%
Accounts Receivable	727.31	737.62	636.88	855.49	157.93	22.14
Other Receivables	10.44	81.11	3.98	0.54	19.15	0.25
Receivables	737.74	818.73	640.87	856.03	177.08	22.4
Inventory	357.84	283.41	352.85	677.78	875.62	170.51
Prepaid Expenses	-	-	0.25	-	-	-
Other Current Assets	52.4	-24.03	57	249.59	454.49	114.07
Total Current Assets	3,939	4,282	5,181	7,730	9,290	5,421
Property, Plant & Equipment	2,631	2,641	3,013	3,069	2,218	873.95
Long-Term Investments	164.6	483.71	446.56	50.12	45.31	265.44
Other Intangible Assets	192.8	115.49	144.15	220.92	172.12	36.9
Long-Term Deferred Tax Assets	211.37	205.39	207.86	196.41	-	-
Long-Term Deferred Charges	130.16	172.21	88.4	51.95	26.19	43.37
Other Long-Term Assets	32.58	57.99	237.53	150.37	122.42	107.78
Total Assets	7,301	7,958	9,319	11,469	11,874	6,748
Accounts Payable	51.38	62.47	103.97	253.12	842.57	60.57
Accrued Expenses	109.35	401.46	454.55	407.25	362.44	157.82
Short-Term Debt	73.21	377.35	883.97	1,530	990.68	-
Current Portion of Long-Term Debt	291.8	513.44	509.17	45.77	90.11	40.16
Current Portion of Leases	-	9.99	64.63	48.76	31.18	8.59
Current Income Taxes Payable	13.24	4.66	0.54	3	29.14	-
Current Unearned Revenue	47.05	14.69	3.57	1.48	193.22	0.42
Other Current Liabilities	501.69	302.68	544.9	635.52	322.08	141.91
Total Current Liabilities	1,088	1,687	2,565	2,925	2,861	409.47
Long-Term Debt	1,052	1,099	1,066	878.01	40	90
Long-Term Leases	8.68	12.68	175.18	198.29	222.85	3.79
Long-Term Unearned Revenue	221.71	250.3	216.72	222.35	201.48	173.96
Long-Term Deferred Tax Liabilities	-	-	-	-	0.56	-
Other Long-Term Liabilities	-	-	8.49	-	-	-
Total Liabilities	2,370	3,048	4,031	4,223	3,326	677.22
Common Stock	247.45	247.45	247.45	247.45	247.45	247.45
Additional Paid-In Capital	6,577	6,577	6,574	6,608	6,598	6,588
Retained Earnings	-1,804	-1,819	-1,440	42.71	1,150	-764.69
Treasury Stock	-89.09	-95.62	-106.17	-150.17	-	-
Comprehensive Income & Other	0.18	0.22	-0.18	0.12	-	-
Total Common Equity	4,931	4,910	5,275	6,748	7,995	6,071
Minority Interest	-	-	12.81	497.51	552.84	-
Shareholders' Equity	4,931	4,910	5,287	7,246	8,548	6,071
Total Liabilities & Equity	7,301	7,958	9,319	11,469	11,874	6,748
Total Debt	1,425	2,012	2,699	2,701	1,375	142.54
Net Cash (Debt)	1,366	1,192	1,431	3,246	6,408	4,971
Net Cash Growth	15.65%	-16.69%	-55.91%	-49.34%	28.90%	745.44%
Net Cash Per Share	5.62	4.82	5.80	13.14	25.91	21.56
Filing Date Shares Outstanding	182.59	249.18	247.04	246.77	247.45	247.45
Total Common Shares Outstanding	182.59	249.18	247.04	246.77	247.45	247.45
Working Capital	2,851	2,596	2,616	4,805	6,428	5,011
Book Value Per Share	27.01	19.70	21.35	27.35	32.31	24.53
Tangible Book Value	4,739	4,794	5,130	6,527	7,823	6,034
Tangible Book Value Per Share	25.95	19.24	20.77	26.45	31.61	24.38
Buildings	-	1,025	978.89	729.03	724.68	37.19
Machinery	-	773.61	1,189	1,050	537.75	120.73
Construction In Progress	-	1,268	1,114	1,342	820.8	760.05

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.